In PNAS this week: genetic diversity of MERS in African camels, centromere evolution in Cryptococcus, and more.
Designed to run on the company's Sentosa real-time PCR system, the test has been approved for identifying and differentiating Zika in patients.
HER3 mRNA expression analysis can predict colorectal cancer patients with wild-type RAS tumors who will respond to panitumumab, US and UK researchers reported.
The British company has announced the results of two studies showcasing the ability of its EpiSwitch platform to diagnose and stage breast cancer and ALS patients.
The multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US, and the firm is also eyeing the Middle East and Africa.
Independent research teams took a look at the mutations, gene fusions, and other alterations that may inform pediatric T-ALL treatment and outcome predictions.
In PLOS this week: gene-environment interactions affecting BMI, transposon mutagenesis study of UTI-linked bacteria, and more.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
Castle will use the proceeds to accelerate marketing and new product development related to its molecular prognostic tests for patients with underserved cancers.
In PLOS this week: RNA-directed DNA methylation in Arabidopsis, TLR5 variants linked to melioidosis survival, and more.
The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.
A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.
Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.
In Science this week: analysis of DNA from ancient North Africans, and more.